Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A prion disease found exclusively among the Fore linguistic group natives of the highlands of new guinea. The illness is primarily restricted to adult females and children of both sexes. It is marked by the subacute onset of tremor and ataxia followed by motor weakness and incontinence. Death occurs within 3-6 months of disease onset. The condition is associated with ritual cannibalism, and has become rare since this practice has been discontinued. Pathologic features include a noninflammatory loss of neurons that is most prominent in the cerebellum, glial proliferation, and amyloid plaques. (From Adams et al., Principles of Neurology, 6th ed, p773)
Biomarker and diagnostic research for kuru has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for kuru.
165 publications have been identified in PubMed for kuru. Kisho has analyzed 80 by research type. Research spans Basic Science / Preclinical (29%), Clinical Trial Publication (26%), and Review / Meta-Analysis (14%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 23 | 29% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 8:40 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
21 |
26% |
Research summaries | 11 | 14% |
Disease patterns and progression | 8 | 10% |
Testing and diagnosis research | 7 | 9% |
Other research | 5 | 6% |
Patient case studies | 3 | 4% |
New treatment approaches | 2 | 3% |
Zincirci DE (2026). [PMID: 41196520](https://pubmed.ncbi.nlm.nih.gov/41196520/). *Ir J Med Sci*. [Clinical Trial Publication]
Çandır EB (2026). [PMID: 41580962](https://pubmed.ncbi.nlm.nih.gov/41580962/). *Bioinformatics*. [Basic Science / Preclinical]
Kuru YA (2026). [PMID: 41652256](https://pubmed.ncbi.nlm.nih.gov/41652256/). *Curr Nutr Rep*. [Review / Meta-Analysis]
Mahat S (2026). [PMID: 32644529](https://pubmed.ncbi.nlm.nih.gov/32644529/). *Unknown Journal*. [Other]
Reith W (2026). [PMID: 41801336](https://pubmed.ncbi.nlm.nih.gov/41801336/). *Radiologie (Heidelb)*. [Review / Meta-Analysis]
Aronson JK (2026). [PMID: 41513265](https://pubmed.ncbi.nlm.nih.gov/41513265/). *BMJ*. [Clinical Trial Publication]
Ekici Zincirci D (2026). [PMID: 42075620](https://pubmed.ncbi.nlm.nih.gov/42075620/). *Medicina (Kaunas)*. [Epidemiology / Natural History]
Kuru K (2026). [PMID: 41930218](https://pubmed.ncbi.nlm.nih.gov/41930218/). *Front Artif Intell*. [Other]
Shipton C (2026). [PMID: 41790047](https://pubmed.ncbi.nlm.nih.gov/41790047/). *Evol Anthropol*. [Review / Meta-Analysis]
Tosev G (2025). [PMID: 40276006](https://pubmed.ncbi.nlm.nih.gov/40276006/). *Eur Urol Open Sci*. [Other]